Dr. Gerald Möller has about 40 years of management experience in the Diagnostic and Pharmaceutical Industries. From 1975-1998 he held several senior management positions in the global organization of Boehringer Mannheim, where he became CEO of the worldwide operating Group in 1995. Following the sale of Boehringer Mannheim to Roche, he became member of Roche’s Executive Committee till December 1998. Moeller was an Investment Advisor to HMB Partners, Switzerland from 2002-2014 and an active participant in the international healthcare/biotechnology sector serving on the board of many innovative growing companies, most of which were successfully sold to large, global healthcare firms. He served five years on the Board of Illumina Inc. which he left in May 2015. He is Chairman of Morphosys AG in Germany.

Rainer Christine was the CEO of the German-American company amaxa from its inception in 1998 until a successful trade sale in 2008. Rainer co-founded the company with his partner Gregor Siebenkotten (AYOXXA investor). By 2008 amaxa employed 160 people, had sales of around €20 Mio and had raised approximately €15 Mio in venture capital. Since then Rainer Christine has been active in the venture capital industry as a private investor.
His focus and core expertise is helping to build AYOXXAs success story.

Dr. Regina Hodits is a General Partner at Wellington since 2011. She studied Chemical Engineering in Vienna and holds a PhD in Biochemistry. Since joining the industry in 2000, she has become an influential investor in the European venture capital industry, focusing on early-stage and growth deals in life sciences.
Her industry experience and her strong scientific background will substantially contribute to AYOXXA´s rapid growth strategy and envisioned goal to set a new standard in the proteomics industry. 

Dr. Markus Hosang is a General Partner and Managing Director at BioMed Partners. He has a strong pharmaceutical and VC background and joined BioMedPartners in 2004. Before he was Venture Partner at MPM Capital, managed their European office in Munich, and served on the board of several portfolio companies. Prior, at Roche, he held for nearly 20 years several senior management positions of increasing importance in the Global Pharma R&D organization. Among other responsibilities, he served on the Global Board of R&D Directors and the Pharma Portfolio Board. Most recently he was VP and CSO of Genetics and Integrated Medicine and a member of the Roche Genetics Executive Committee.

Dr. Hosang received his M.S. and Ph.D. degrees in Biochemistry from the ETH in Zurich, and pursued his postgraduate training at Stanford University Medical School and at the University of Washington in Seattle. He is Vice Chairman of the Board of Directors of Unitectra AG, the joint technology transfer office of the universities of Zurich, Basel and Bern.

Since April 2017 Dr. Aristotelis Nastos is Head of Life Science and Cleantech and responsible for the investment activities of NRW.BANK in these markets. At the same time he is the Managing Partner of the regional early stage Venture Capital Fonds Gründerfonds Ruhr. Previously, he has been Partner at Creathor Venture one of the most renowned venture capital companies in Germany. He holds a number of board positions within the life sciences industry and has been instrumental in various important financings and M&A transactions, such as the sale of Direvo to Bayer. He holds a PhD in Biology and as an International Fellow of The Wellcome Trust (UK) and has also worked as Post Doc at King’s College, London.

Karlheinz Schmelig is Managing Partner at Creathor Venture focusing on life sciences and healthtech investments. He has a broad background in private equity and venture capital and has been working in the industry for over 15 years. Before joining Creathor Venture, Karlheinz Schmelig worked as an investment director at various VC firms. Prior to his venture capital career he worked successfully for over ten years in a number of global management positions in the healthcare industry at Boehringer Mannheim and F. Hoffmann-La Roche. Karlheinz Schmelig studied business in Mannheim and holds an MBA from the Kelly School of Business at Indiana University.

Dr. Andreas Schmidt is a Co-Founder of AYOXXA Biosystems GmbH. While leading AYOXXA as CEO until October 2016, the company developed its core technology and expanded to about 35 employees operating from three sites in Cologne, Singapore and Boston. Andreas Schmidt obtained a PhD in molecular and cell biology jointly from the University of Cologne and the University of California, Berkeley and he received several prestigious fellowships and awards in the USA, Germany, China, Taiwan and Singapore. Dr. Schmidt served on the advisory board of the German Academic International Network (GAIN) for North America and is a board member, advisor and mentor for several biotech companies.

Rodney Turner assumed duties as CEO of AYOXXA in October 2016. Prior to this, he was an independent board member. With almost ten years of experience as senior Corporate Development executive with Life Technologies, he has excelled as a senior business development executive, contributing to the growth of numerous biotech startups in the US and Germany over the past 20 years.